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ABSTRACT  
 
Objective 
To determine the effects of improved home ventilation on house dust mite levels and 
the control of asthma.    
 
Design 
A randomized double-blind placebo-controlled parallel group trial.   
 
Setting 
Participants were recruited from General Practice and Hospital Respiratory Clinics in 
the West of Scotland.  
 
Participants 
120 adults with asthma who were allergic to house dust mite Dermatophagoides 
pteronyssinus. 
 
Interventions 
Mechanical heat recovery ventilation (MHRV) units were installed in all homes.  Half 
of the units were activated at randomisation. All homes had carpets steam cleaned and 
new bedding and mattress covers at baseline. 
 
Main outcome measures  
The primary outcome was morning peak expiratory flow at 12 months. 
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Results 
At 12 months, the change in mean morning peak expiratory flow, as compared with 
baseline, did not differ between the mechanical ventilation group and the control 
group [mean difference 13.5 liters per minute, 95% CI. -2.6 to 29.8, p=0.100]. 
However, evening mean peak expiratory flow was significantly improved in the 
mechanical ventilation group [mean difference 24.5 liters per minute, 95% CI. 8.9 to 
40.1, p=0.002] and there were fewer hospitalizations for asthma (0 vs. 4, p=0.029). 
Indoor relative humidity was reduced in mechanically ventilated homes, but there was 
no difference between the groups in Der p 1 levels, compared with baseline, to 
account for the clinical changes. 
 
Conclusions 
The addition of mechanical heat recovery ventilation to conventional house dust mite 
eradication strategies did not achieve a reduction in house dust mite levels, but did 
improve some indices of asthma control.  
 
Trial registration 
 ClinicalTrials.gov number NCT00148096 
 
Words count: 252  
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INTRODUCTION 
 
The prevalence of asthma in the western world has increased over the last generation,1 
in parallel with a warmer indoor microclimate.2 Increased insulation, double glazing 
and modern building construction have improved standards of heating and energy 
efficiency in homes, but with reduced ventilation.3 A warm, humid indoor 
environment favours the growth of the house dust mite population.4 Sensitivity to the 
house dust mite is the most common allergy associated with asthma in the UK.5 
 
Studies of occupational asthma6 and altitude7 infer that the environment may directly 
affect symptoms of asthma. Accordingly, allergen avoidance has been advocated as 
an important aspect of asthma management, yet the evidence for its efficacy is 
limited.8 Large studies of conventional measures to eradicate dust mites, such as mite-
impermeable mattress covers, have not shown a benefit for asthma symptoms.9,10 
However, Morgan et al11 found significant improvement in asthma when a number of 
allergens were targeted in combination with an educational intervention and smoking 
cessation advice. 
 
 As house dust mites thrive in moist conditions, an additional eradication strategy 
would be to reduce indoor air humidity by improving ventilation. Mechanical heat 
recovery ventilation is a method of active ventilation using both an extract and a 
supply fan. Outdoor air is supplied at ambient humidity into the living room and 
bedroom, and extracted from the kitchen and bathroom. There is evidence that 
mechanical ventilation reduces indoor air humidity and the house dust mite allergen 
burden, but the clinical effects on asthma have not been proven.12,13 The hypothesis is 
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that domestic mechanical heat recovery ventilation, in addition to allergen avoidance 
measures,  can improve asthma control of those sensitive to house dust mite allergen, 
by attenuating re-colonisation rates.  
 
METHODS   
 
Participants 
 
Participants 16 to 60 years of age were eligible if they had asthma for more than one 
year, were on regular inhaled corticosteroids and had daily symptoms. Participants 
were recruited from general practice and hospital clinics in Lanarkshire, Scotland, 
UK. Variable airflow obstruction of ≥12% on spirometry14 or ≥15% on peak 
expiratory flow (PEF) readings15 or a symptom score of ≥0.86 on the Asthma Control 
Questionnaire (ACQ)16,17 was required for inclusion. Participants had a minimum 
forced expiratory volume in 1 second (FEV1) of  >50% predicted at baseline and had 
not had an exacerbation in the previous month. Spirometric measurements were 
recorded using an electronic spirometer (Vitalograph, Buckingham, UK), before and 
after inhaled salbutamol (400 µg).18 PEF measurements were taken at home using a 
mini-Wright peak flow meter (Clement Clarke, Harlow, UK). Allergy to D. 
pteronyssinus was determined by positive skin prick test, defined as a wheal diameter 
of ≥3mm greater than negative control at 15 minutes; solutions supplied by ALK 
Abello, Hungerford, UK.19 Participants were excluded if they were likely to move 
house or had a pet that provoked their symptoms. Participants were enrolled in the 
study by the clinical team between April 2003 and November 2005.The Lanarkshire 
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Research Ethics Committee approved the study. All participants gave written 
informed consent.  
 
Study design 
 
This was a randomised, double-blind, placebo-controlled, parallel group study to 
evaluate the effect of home installation of mechanical heat recovery ventilation 
(MHRV), in addition to conventional eradication strategies, in adults with asthma 
who were sensitive to Dermatophagoides pteronyssinus.  
 
MHRV system 
Homes of eligible participants were surveyed to assess suitability for installation. 
Homes were excluded if installation was technically difficult or if there was asbestos 
in ceiling materials.   MHRV units (HR250 or HR800) were fitted in the roof space or 
hallway cupboard in 120 suitable homes by ‘Vent-Axia™’ (Crawley, UK). These 
energy efficient units extract air continuously from the kitchen and bathroom and 
deliver pre-warmed air via insulated ducts into the bedroom and living room (Figure 
1). The system provided an additional 0.5 air exchanges per hour to the living room 
and bedroom.   
 
Clinical assessments 
Participants attended a baseline visit where spirometry was recorded and the ACQ16 
and St. George’s Respiratory Questionnaire20 were completed. The EQ-5D 
questionnaire'21 was used as a standardised generic instrument for valuing health-
related quality of life. Each score is categorised and ‘quality of life years’ (QALYs) 
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can be calculated from the difference in health states due to an intervention. 
Participants compiled a 2-week PEF diary prior to the visit. Nasal symptoms were 
recorded on a visual analogue score.22 Serum total IgE and D. pteronyssinus and 
pollen-specific IgE were measured by commercial enzyme-immunoassay23 (Sweden 
Diagnostics Ltd, Milton Keynes, UK).  
 
House dust allergen, humidity and other environmental measurements 
The architect team attended the home for a baseline visit. The bedroom, living room 
floor and bed surface were vacuumed at a rate of 1m2 per minute to obtain complete 
dust samples using a Dyson model - DC14 (Dyson, London, UK). The dust samples 
were filtered and weighed and a standardised soluble extract prepared. The extract 
concentration of allergens from house dust mite (Der p 1, Der p 2), cat dander (Fel d1) 
and dog dander (Can f1) were measured using fluorescent multiplex array technology 
(Indoor Biotechnologies, Charlottesville, VA).24 The microbial content of dust was 
estimated by measuring soluble extract concentrations of bacterial endotoxin and 
fungal β(1-3) glucan (Associates of Cape Cod Inc., East Falmouth, MA, USA). 
Plasma cotinine was measured using a microplate competitive enzyme immunoassay 
(Cozart Bioscience Ltd, Abingdon, Oxford, U.K.), 
 
Temperature and humidity were recorded at 90 minute intervals for 12 months in the 
living room and bedroom using thermohygrographs, ‘Gemini Tiny Tag Ultra two 
channel’ dataloggers (Gemini, Chichester, UK). The critical equilibrium humidity, at 
which no water is gained or lost by the house dust mite, is 73% relative humidity at 
25ºC.4  As maintaining relative humidity below 50% is a common recommendation 
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for reducing dust mites in the home,25 the proportion of time that relative humidity 
fell below 50% was calculated.  
 
Allergen avoidance measures 
Once baseline measurements were complete, allergen eradication took place in all 
homes. Carpets were cleaned with a "Medivac" steam cleaner at the rate of 1m2 per 
minute (Medivac Healthcare Ltd., Cambridge, UK). New pillows, duvets and mattress 
covers were supplied to all participants ("Naturelle" range, Medivac Healthcare Ltd., 
Cambridge, UK).   
 
Randomisation 
Randomisation was performed in sequential blocks of four using an automated 
telephone answering system at the Robertson Centre for Biostatistics, University of 
Glasgow, UK, by the architect team. Accordingly, a fused electrical spur was 
switched in the roof space by the architect to activate half of the units. The unit 
activation device was concealed from the patient and the clinical research team.  
 
Follow-up 
Participants were followed up at 3, 6, 9 and 12 months after randomisation, until April 
2007.  Participants measured morning and evening PEF for 2 weeks before each visit. 
At each visit, spirometry was performed, ACQ score was recorded and requirements 
for oral corticosteroids, hospitalisations, General Practice or Emergency Department 
visits were noted. The St. George’s Respiratory questionnaire, the EuroQol 
questionnaire and nasal visual analogue scores and questionnaires were repeated at 6 
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and 12 months after randomisation. At 12 months, blood samples for IgE serology, 
dust samples and humidity measurements were taken and placebo units activated. 
 
Statistical analysis 
 
The sample size was based upon a parallel group design, using a standard deviation of 
40 liters/min for mean morning PEF. The study was intended to have 64 evaluable 
participants per group (n=128), in order to have 80% power (at the 5% significance 
level) to calculate a difference of 20 liters/min.   
 
The primary analysis was a comparison between groups of the change over baseline 
in morning PEF. Secondary endpoints were evening PEF, ACQ scores, exacerbation 
and hospitalisation rates, spirometry, quality-of-life, Der p 1 levels and humidity 
readings in the homes, IgE levels and economic evaluations. If 12 month data were 
not available, 9 month data would be used instead. The main analyses were carried 
out with ANCOVA models adjusted for baseline severity. The analyses were firstly 
carried out on an intention to treat basis. A list of ‘major protocol violators’ consisting 
of those with premature activation by the electrician and randomisation errors was 
created and the remaining population were denoted the ‘per protocol’ set. The primary 
and secondary endpoints were repeated for the ‘per protocol’ set. Binary endpoints 
such as hospitalizations were compared by odds-ratios, the attendant 95% confidence 
interval and tested by Mantel-Haenszel chi-squared test. 
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RESULTS 
 
Baseline characteristics of participants 
A total of 4986 participants were invited to participate, 482 attended clinical 
screening and 216 fulfilled the clinical entry criteria (Figure 2). Fifty-three subjects 
did not fulfill all housing criteria and 43 did not wish to have the MHRV unit 
installed. Units were installed in 120 homes, 119 underwent randomisation. Baseline 
demographic characteristics of those randomized were similar (Table 1).  
 
Outcome measures 
 
Clinical outcomes 
100 participants attended follow-up at 12 months. The clinical outcome measures are 
listed in Table 2. The change in mean morning PEF did not differ between the MHRV 
group and the control group [mean difference 13.5 litres per minute, 95% CI -2.6 to 
29.8, P=0.100]. However, there was a significant improvement in the MHRV group 
compared to the control group in mean evening PEF [mean difference 24.5 litres per 
minute, 95% Cl 8.9 to 40.1, P= 0.002] (Figure 3).  
 
The ACQ score significantly improved in the MHRV group at 3 months [mean 
difference, -0.44, 95% Cl -0.76 to -0.12, p=0.008], but not thereafter.  There were 
statistically fewer hospitalisations for asthma over the 12 month period in the MHRV 
group than in the control group (0 vs. 4, p=0.029). Values for spirometry, use of 
rescue medication, St. George’s Respiratory Questionnaire score, requirements for 
oral corticosteroids, General Practitioner or Emergency department visits with asthma 
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did not differ between the two groups.  Rhinitis visual analogue scores for sneezing, 
nasal discharge and nasal blockage significantly improved in the MHRV group 
compared to the control group at 6 months [sneezing, mean difference, -1.07, C.L. –
2.05 to -0.10, p=0.032; nasal discharge, mean difference, -1.36, 95% Cl -2.30 to -
0.42, p=0.005; nasal blockage, mean difference, -1.65, 95% Cl -2.74 to -0.56, 
p=0.004], but not at 12 months. In the economic analysis there was a gain of 0.02 
QALYs per MHRV patient.  Eighteen major protocol violators were excluded from 
the ‘per protocol’ analysis. Fifteen were due to premature activation of the unit by the 
site electrician and three were randomisation errors. The ‘per protocol’ analysis 
confirmed that of the intention-to-treat analysis. Exacerbations of asthma are reported 
in Table 2 on page 27. No adverse events were reported relating to the installation of 
the MHRV unit.  
 
Indoor relative humidity and temperature 
MHRV significantly reduced mean relative humidity in the bedrooms for a sustained 
period from October until February and in the living room from December to 
February (Figure 4). The median (range) percent of time homes achieved a reduction 
in the indoor relative humidity below 50% was greater in the MHRV group than in 
the control group in the bedroom [44.1% (range 6.6% to 95.5%) vs. 28.9% (range 
0.2% to 81.7%), p=0.001] but not in the living room [47.0% (range 9.9% to 93.3%) 
and 39.5% (0.5% to 83.2%), p=0.256]. 
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Concentration of allergens and microbial products in house dust, and serum IgE 
levels 
At 12 months, the changes in mean Der p 1 and Der p 2 concentrations in the bed,   
bedroom and living room carpets, as compared with baseline concentrations, did not 
differ between the MHRV group and the control group, nor were there differences in 
total or house-dust mite specific IgE. There were also no significant differences  in 
secondary analyses of cat dander allergen (Fel d1), dog dander allergen (Can f1), β (1-
3) glucan or endotoxin. (Table 2) 
 
DISCUSSION 
 
This randomised, double-blind placebo-controlled study examined the effect of the 
installation of domestic mechanical heat recovery ventilation (MHRV) on asthma 
control in adults sensitive to house dust mite allergen. It was based on the hypothesis 
that a warm, humid environment favours growth of the house dust mite population 
and that decreasing indoor air humidity with mechanical ventilation would reduce the 
dust mite allergen burden and improve asthma control.  
 
Statement of principal findings 
We found that there were improvements in some indices of asthma control at 12 
months: increased evening PEF and fewer hospital admissions with asthma.  Indoor 
relative humidity was reduced in the autumn and winter months in ventilated homes, 
but there was no difference between Der p 1 levels between the groups to account for 
the clinical changes. There were improvements in ACQ and Rhinitis visual analogue 
scores in the MHRV group after 6 months, which were short lasting, and may imply 
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that the MHRV intervention was most effective when combined with recent mite 
eradication strategies.  
 
Strengths and weaknesses of the study 
The strengths of the study are that it was a large community-based randomised  trial 
utilising expertise from different disciplines.  Participants reflected the general 
population with asthma with a GP diagnosis of asthma, daily symptoms and house 
dust mite sensitivity were sufficient for inclusion. Randomisation was effectively 
concealed from the participants and the clinical team. As 100 of a projected optimum 
number of 128 participants completed follow-up, the power of the study may not have 
been sufficient to detect a significant change in morning PEF.  
 
Relation to previous research 
Two previous small studies have examined the efficacy of MHRV for asthma. Warner 
and colleagues12 showed a non-significant improvement in histamine PC20 (p=0.085), 
but no change in lung function or symptom scores with MHRV and high energy 
vacuum cleaning. Htut26 found a decrease in bronchial hyperreactivity at 12 months 
after MHRV and steam cleaning. Our study provides weight to the evidence that 
improved ventilation might have a beneficial effect on asthma control.  
 
Although the Der p 1 and Der p 2 levels fell in both groups, there was no difference 
between the MHRV group and the control group, adjusted for baseline. There was no 
difference between the groups in change in serum house-dust mite specific IgE 
antibody.  This suggests that the MHRV system reduced indoor relative humidity to 
levels that were insufficient to impact on mite levels. Maintaining relative humidity 
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below 50% is a common recommendation for reducing dust mites in the home.25 The 
MHRV unit achieved a relative humidity less than 50% in the winter months in the 
bedrooms more frequently than in the control group. However, although it may be 
statistically significant, it may not be environmentally significant as the fluctuation of 
humidity levels may permit mite survival. For example, a New Zealand study27 
showed that, although active ventilation did reduce relative humidity to less than 50% 
for 7 months of the year, there were no effects on mite levels because values were 
below the critical equilibrium humidity for only 39% of the total of 24-hour periods 
for which measurements were made. In another UK study, Fletcher30 also found no 
impact of MHRV on Der p 1. It is possible that 12 months was too short a period to 
measure a difference in seasonally affected mite re-colonisation rates, after steam 
cleaning and barrier bedding were implemented across both cohorts. 
 
One reason for this lack of efficacy in mite control may be related to climate.29 For 
ventilation to reduce indoor humidity, the outdoor air humidity must be sufficiently 
lower than that inside. A Danish study observed 11 subjects with allergic asthma who 
were moved to ‘healthy’ homes with MHRV and found that a reduction of indoor 
absolute humidity was associated with a fall in dust mites and an improvement in 
indices of asthma control. However, there is an important difference between the cold 
winters of Scandinavia where the ambient air relative humidity was very low, 
compared with the high humidity ambient wet air during the milder winters of 
temperate regions of western Europe and New Zealand. Based on these observations, 
a future development in the intervention would be a humidistat controller (set at 50%) 
linked to a variable flow fan unit to ensure humidity suppression during the colder 
months. 
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Unanswered questions and future research  
As the beneficial clinical effect of MHRV is not explained by a reduction in exposure 
to house dust mites, which other alternative explanations can be considered? No 
difference in cat or dog allergens, or in bacterial endotoxin levels in dust samples was 
demonstrated between the groups. Maintaining relative humidity below 50% has been 
recommended for controlling mould.31 Burr and co-workers recently conducted an 
unblinded mold eradication trial that included improved home ventilation and found 
symptomatic improvement in wheeze, medication use and rhinitis.32  In our study no 
difference between fungal glucan exposure was observed between the groups. Other 
possible explanations are a reduction in environmental tobacco smoke, respiratory 
viruses33 or another component of indoor air quality such as particulate matter or 
volatile organic compounds. Increased relative humidity by itself is reported to be 
sufficient for increasing respiratory and other general symptoms.34,35  There appears to 
be a dose-response relationship between asthma and living in damp housing, with 
respiratory symptoms more common in subjects living in damp homes. Action to 
improve damp housing conditions may therefore favourably influence asthma 
morbidity. 
Finally, in the MHRV group there was gain of 0.02 QALY per subject. If the cost of 
installation is approximately £2000, the small QALY gain comes at a high price, 
albeit offset by a small reduction in hospitalisations. However, if the clinical results 
are sustained for the lifetime of the MHRV unit (10-20 years), the intervention may 
be more cost-effective. 
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In conclusion, this randomised controlled trial has shown clinical benefits of 
improved home ventilation in asthma control not explained by reduced levels of house 
dust mites. Future research should determine the mechanism of this effect. 
 
 
 
‘What this paper adds’ box 
What is already known on this subject 
House dust mite allergy is commonly associated with asthma.  The warm, humid 
environment in modern homes favours the house dust mite population.  The effect of 
improved ventilation on asthma control is not known. 
What this paper adds 
This randomised controlled trial has shown clinical benefits of improved home 
ventilation in asthma control. However, this was not explained by reduced levels of 
house dust mites. Future research should determine the mechanism of this effect.  
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Table 1. Baseline Demographic and Clinical Characteristics 
Characteristic MHRV Group Control Group 
No. of participants 60 59 
Age (years) 
 
41.6 (±9.6) 42.3 (±10.7) 
Gender 
Female - no. (%) 
41 (68.3) 32 (54.2) 
Race or ethnic group -no. (%) 
    Caucasian  
    Asian 
  
58 (96.7) 
2 (3.3 ) 
 
58 (98.3)  
 1 (1.7) 
Smoking –no. (% ) 
    Smoker 
    Ex-smoker 
    Never smoker 
 
Plasma cotinine [all subjects] 
ng/ml, median (IQR) 
 
12 (20.0) 
7 (11.7) 
41 (68.3) 
 
 
3.4 (2.0-63.0) 
 
17 (28.8) 
13 (22.0) 
29 (49.1) 
 
 
3.2 (2.0-68.0) 
Duration of asthma (years) 
 
22.1 (±14.1) 20.1 (±13.9) 
BMI (kg/m²) 
 
28.4 (±5.5) 29.6 (±6.3) 
Morning PEF (litres/min) 
 
414.5 (±116.9) 409.1 (±91.6) 
Evening PEF (litres/min) 
 
428.2 (±112.4) 426.9 (±94.9) 
Spirometry (% predicted) 
    FEV1  Prebronchodilator 
               Postbronchodilator 
    FVC   Prebronchodilator 
 
 
83.7 (±18.0) 
86.6 (±18.1) 
93.5 (±13.6) 
 
 
82.7 (±17.7) 
89.5 (±15.6) 
95.0 (±15.4) 
 
No. of puffs of a short-acting  
β-agonist (daily) 
 
3.5 (±2.5) 4.0 (±3.7) 
Asthma Control 
Questionnaire Score  
(0 to 6)   
 
 
2.0 (±1.1) 
 
2.0 (±1.0) 
St. George’s Questionnaire Score  
(0 to 100%) 
35.3 (±23.9) 
 
 
34.6 (±20.4) 
 
 
Co-morbidity no. (%) 
     Hypertension 
     Previous Myocardial infarction 
     Previous Stroke 
     Angina 
     Diabetes 
     Hayfever or other nasal allergy 
     Eczema 
     Other respiratory  
     
 
5 (8.3) 
0 (0.0) 
1 (1.7) 
2 (3.3) 
3 (5.0) 
44 (73.3) 
15 (25.0) 
0 (0.0)  
 
8 (13.6) 
1 (1.7) 
2 (3.4) 
3 (5.1) 
2 (3.4) 
47 (79.7) 
14 (23.7) 
1 (1.7) 
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Characteristic 
 
MHRV Group Control Group 
Inhaled corticosteroid-  
beclomethasone  equivalent  
µg, median (IQR) 
 
 
 
1000 (800-2000) 
 
 
800 (400-1200) 
Current other asthma medication 
No. (%) 
     β2-agonist (short-acting inhaled) 
     β2-agonist (short-acting oral) 
     β2-agonist (long-acting) 
     Theophylline 
     Anti-cholinergic 
     Leukotriene receptor antagonist 
     Oral steroid 
 
 
 
60 (100.0) 
1 (1.7) 
41 (68.3) 
4 (6.7) 
5 (8.3) 
15 (25.0) 
4 (6.7) 
 
 
58 (98.3) 
1 (1.7) 
34 (57.6) 
4 (6.8) 
6 (10.2) 
9 (15.3) 
3 (5.1) 
Rhinitis visual analogue scale  
(1 to 10) 
    Sneeze 
    Nasal discharge 
    Nasal blockage 
     
 
 
4.3 (±3.1) 
3.7 (±3.1) 
4.7 (±3.0) 
 
 
 
4.2 (±2.7) 
4.3 (±3.1) 
4.8 (±3.1) 
 
Serum IgE antibody 
HDM (kUA/L) 
 
15.8 (±25.8) 
 
20.4 (±31.6) 
 
Der p 1 (µg per gram of dust) 
Bed 
Bedroom carpet 
Living room carpet 
 
4.9 (±14.4) 
3.0 (±7.5) 
2.7 (±7.4) 
 
2.2 (±5.1) 
1.7 (±3.6) 
3.1 (±6.2) 
 
Definition of abbreviations: No., number; Plus-minus values are means ± Standard 
Deviation; HDM, house dust mite. 
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Table 2.  Comparison of clinical outcomes at baseline and 12 months. 
 
Outcome 
 
 
MHRV 
(mean ± SD)           
Placebo 
(mean ± SD)          
 
Adjusted  difference 
ANCOVA (95% Cl) 
p value 
PEF am 
(litres/min) 
Baseline 
12 months 
Change 
 
 
414.5±116.9 
419.2±127.9 
6.4±38.8 
 
 
409.1±91.6 
395.8±96.0 
-7.1±38.5 
 
 
 
 
13.59 (-2.66 to 29.85) 
 
 
 
 
0.100 
 
PEF  pm 
(litres/min) 
Baseline 
12 months 
Change 
 
 
428.2±112.4 
436.1±124.7 
12.0±36.4 
 
 
426.9±94.9 
405.9±93.4 
-12.4±37.9 
 
 
 
 
24.56 (8.97 to 40.15) 
 
 
 
 
0.002 
 
ACQ 
(0-6) 
Baseline 
12months  
Change 
 
 
2.0±1.1 
1.5±1.1 
-0.4±0.7 
 
 
2.0±1.0 
1.8±1.1 
-0.1±1.0 
 
 
 
 
-0.25 (-0.57 to 0.08) 
 
 
 
 
0.141 
 
Rescue meds 
(no. of puffs) 
Baseline 
12 month 
Change 
 
 
3.5±2.5 
3.5±2.8 
0.0± 1.9 
 
 
4.0±3.7 
3.5±3.4 
0.1±2.3 
 
 
 
 
-0.04 (-1.00 to 0.92) 
 
 
 
 
0.936 
 
St George’s 
(0-100)  
Baseline 
12 months 
Change 
 
 
35.3±23.0 
29.7±24.4 
-5.2±13.7 
 
 
34.6±20.4 
31.2±19.9 
-2.1±12.4 
 
 
 
 
-2.83 (-7.82 to 2.16) 
 
 
 
 
0.262 
 
FEV1 pre 
(% predicted) 
Baseline 
12 month 
Change 
 
 
83.7±18.0 
86.6±18.1 
1.8±8.3 
 
 
82.7±17.7 
82.5±16.9  
1.0±11.3   
 
 
 
 
1.32 (-2.56 to 5.19) 
 
 
 
 
0.502 
 
Exacerbations 
number 
Oral steroids 
ED visits 
GP visits 
GP out of hours  
Hospitalisations 
 
 
12  
4 
0 
24 
0 
 
 
17  
2 
1 
22 
4 
 
 
0.51 (0.21-1.22) 
1.78 (0.31-10.16) 
 
0.90 (0.42-1.93) 
 
 
0.124 
0.512 
0.282 
0.795 
0.029 
 
Sneezing 
VAS 
Baseline 
6 months 
Change 
12 months 
Change 
 
 
4.3 (±3.1) 
2.9 (±2.4) 
-1.1 (±2.8) 
2.6 (±2.6) 
-1.7 (±3.0) 
 
 
4.2 (±2.7) 
4.1 (±2.9) 
0.0 (±2.8) 
3.1 (±2.3) 
-0.8 (±2.3) 
 
 
 
 
-1.07 (-2.05 to -0.10) 
 
-0.76 (-1.70 to 0.18) 
 
 
 
 
0.032 
 
0.111 
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Nasal discharge 
VAS 
Baseline 
6 months 
Change 
12 months 
Change 
 
 
3.7 (±3.1) 
2.7 (±2.7) 
-0.8 (±2.5) 
2.7 (±2.9) 
-0.9 (±3.1) 
 
 
4.3 (±3.1) 
4.3 (±2.8) 
0.4 (±2.8) 
3.4 (±2.4|) 
-0.5 (±2.7) 
 
 
 
 
-1.36 (-2.30 to -0.42) 
 
-0.46 (-0.47 to 0.55) 
 
 
 
 
0.005 
 
0.371 
 
Nasal blockage 
VAS 
Baseline 
6 months 
Change 
12 months 
Change 
 
 
4.7 (±3.0) 
3.1 (±2.8) 
-1.3 (±2.8) 
3.7 (±3.0) 
-0.9 (±3.1) 
 
 
4.8 (±3.1) 
4.3 (±2.8) 
0.3 (±3.2) 
4.0 (±3.0) 
-0.5 (±3.2) 
 
 
 
 
-1.65 (-2.74 to -0.56) 
 
-0.51 (-1.68 to 0.66) 
 
 
 
 
0.004 
 
0.392 
 
Der p 1 (µg/g) 
Bed 
Baseline 
12 months 
Change 
 
 
4.9 (±14.4) 
0.7 (±1.5) 
-3.2 (-6.7 to 0.4) 
 
 
2.2 (±5.1) 
2.6 (±9.6) 
-1.3(-2.3 to -0.2) 
 
 
 
 
-0.32 (-0.84 to 0.21) 
 
 
 
 
0.232 
 
Der p 1(µg/g) 
Living Room 
Baseline 
12 months 
Change 
 
 
2.7 (± 7.4) 
0.9 (± 2.0) 
-1.9 (-4.0 to 0.2) 
 
 
3.1(± 6.2) 
1.0(± 2.1) 
-2.8(-4.7 to -0.9) 
 
 
 
 
0.1 (-0.8 to 0.9) 
 
 
 
 
0.850 
 
Der p 1 (µg/g) 
Bedroom carpet 
Baseline 
12 months 
Change 
 
 
3.0 (±7.5) 
2.3 (±11.1) 
-0.4 (-4.7 to 3.8) 
 
 
1.7 (±3.6) 
1.5 (±1.8) 
-0.5 (-1.6 to 0.6) 
 
 
 
 
1.46 (-2.65 to 5.57) 
 
 
 
 
0.482 
 
Der p 2 (µg/g) 
Bed 
Baseline 
12 months 
Change 
 
 
1.1 (±2.2) 
0.3 (±0.7) 
-0.6(-1.0 to -0.3) 
 
 
0.9±2.1 
1.0±4.0 
-0.6 (-1.0 to -0.1) 
 
 
 
 
-0.04 (-0.16 to 0.08) 
 
 
 
 
0.496 
 
Der p 2(µg/g) 
Living room 
Baseline 
12 months 
Change 
 
 
1.2±3.1 
0.9±3.3 
-0.2 (-1.5 to 1.1) 
 
 
1.4±3.1 
0.5±1.3 
-1.3 (-2.4 to -0.2) 
 
 
 
 
0.56(-0.65 to 1.77) 
 
 
 
 
0.359 
 
Der p 2 (µg/g) 
Bedroom carpet 
Baseline 
12 months 
Change 
 
 
1.7±3.6 
1.6±7.3 
0.1(-2.4 to 2.7) 
 
 
1.0±2.0 
0.9±1.3 
-0.3 (-0.7 to 0.2) 
 
 
 
 
1.07(-1.63 to 3.76) 
 
 
 
 
0.433 
 
Cat allergen 
Bed 
Baseline 
12 months 
Difference 
 
 
2.9±5.5 
3.3±5.6 
0.0(-1.3 to 1.4) 
 
 
3.3±0.6 
3.4±0.2 
0.4(-1.7 to 2.5) 
 
 
-0.29(-2.63 to 2.06) 
 
 
 
 
0.809 
 
 28
Cat allergen 
Living Room 
Baseline 
12 months 
Difference 
 
 
2.1±3.8 
3.5±5.9 
1.1(-0.5 to 2.7) 
 
 
2.7±5.0 
4.6±7.9 
2.9(0.8 to 5.0) 
 
 
 
 
-1.81(-4.35 to 0.73) 
 
 
 
 
0.161 
 
Cat allergen 
Bedroom carpet 
Baseline 
12 months 
Difference 
 
 
3.1±5.4 
3.6±5.1 
0.3(-1.1 to 1.8) 
 
 
4.0±7.8 
3.3±5.6 
-1.1(-3.9 to 1.7) 
 
 
 
 
0.61(-1.59 to 2.81) 
 
 
 
 
0.582 
 
Dog allergen 
Bed 
Baseline 
12 months 
Difference 
 
 
22.2±41.8 
25.4±56.1 
-1.7(-12.1 to 8.7) 
 
 
21.5±3.8 
11.0±31.7 
-8.4(-23.5 to 6.7) 
 
 
7.22(-8.64 to 23.07) 
 
 
 
 
0.368 
 
Dog allergen 
Living Room 
Baseline 
12 months 
Difference 
 
 
97.7±461.4 
41.9±71.9 
-67.1(-207.1 to 73.0) 
 
 
29.8±50.8 
34.8±53.1 
5.8(-11.9 to 23.4) 
 
-3.17(-29.36 to 23.03) 
 
 
 
 
0.811 
Dog allergen 
Bedroom Carpet 
Baseline 
12 months 
Difference 
 
 
 
29.8±57.9 
34.4±59.1 
-1.4(-13.9 to 11.2) 
 
 
26.2±54.1 
26.2±4.1 
7.2(-6.6 to 21.1) 
 
 
 
 
-5.20(-22.49 to 12.09) 
 
 
 
 
0.551 
 
IgE to HDM 
Baseline 
12 months 
Change 
 
 15.8 (± 25.8) 
15.5 (± 24.2) 
-0.3 (±21.7) 
 
20.4(± 31.6) 
16.5 (± 26.1) 
-3.8 (±13.9) 
 
2.09 (-5.67 to 9.85) 
 
            
 
0.592 
Mold  
β(1-3) glucan 
Living Room 
(µg/g dust) 
Baseline 
12 months 
Change 
 
  
 
 
322.0(±453.2 ) 
108.9(±111.7) 
-241.6(±486.9) 
 
 
 
 
390.8(±582.2) 
113.4(±37.2) 
-360.7(±657.0) 
 
 
 
 
 
 
-7.8 (-26.0 to 10.2) 
 
 
 
 
 
 
0.389 
 
Mold  
β(1-3) glucan 
Bed (µg/g dust) 
Baseline 
12 months 
Change 
 
 
 
347.1(±483.3) 
99.3(±50.8) 
-273.9(±544.5) 
 
 
 
255.5(±304.1) 
77.8(±35.4) 
-214.3(±366.4) 
 
 
 
 
 
22.7 (-0.4 to 45.9) 
 
 
 
 
 
0.055 
 
Mold  
β(1-3) glucan 
Bedroom carpet 
(µg/g dust) 
Baseline 
12 months 
Change 
 
 
 
 
351.5(±966.6) 
107.5(±39.4) 
-270.5(±1063.7) 
 
 
 
 
226.9(±216.9) 
114.2(±64.9) 
-142.6(±233.8) 
 
 
 
 
 
 
-15.4 (-40.4 to 9.5) 
 
 
 
 
 
 
0.222 
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Endotoxin (EU) 
Bed 
Baseline 
12 months 
Change 
 
 
3539(±3213.8) 
4583 (±3450.3) 
1109 (±3934.9) 
 
 
4479 (±3475.9) 
5952 (±3617.5) 
1253 (±4969.5) 
 
 
 
 
-1187.5 (-2935.7 to 560.7) 
 
 
 
 
0.180 
Endotoxin (EU) 
Living Room 
Baseline 
12 months 
Change 
 
  
5136.2(±2990.8) 
7776.9(±2548.9) 
2666.1(±4488.0) 
 
 
6318.4(±2891.1) 
6986.0(±2589.9) 
555.6(±4418.9) 
 
 
 
 
497.2 (-679.6 to 1674.1) 
 
 
 
 
 0.403 
 
Endotoxin (EU) 
Bedroom carpet 
Baseline 
12 months 
Change 
 
 
5725 (±3202.5) 
6996 (±3047.0) 
1148 (±4541.9) 
 
 
5005 (±3438.0) 
6916 (±2754.5) 
1902 (±3823.0) 
 
 
 
 
-64.6 (-1465.6 to 1336.28) 
 
 
 
 
 
0.927 
 
Definition of abbreviations: Data represented as mean (+/- Standard Deviation), CI 
confidence interval. Values represent mean difference (CI) compared with baseline. Peak 
expiratory flow rate (PEF), Forced expiratory volume in 1 second (FEV1), Asthma Control 
Questionnaire (ACQ) score (range, 0 to 6, with higher scores indicating worse asthma 
control). St. George’s Respiratory Questionnaire (range, 0 to 100, with higher scores 
indicating worse quality of life). ED, Emergency Department, GP, General Practitioner.  
Rhinitis VAS, visual analogue scale (range, 1 to 10, with higher scores indicating worse 
symptoms). Immunoglobulin E (IgE), Dermatophagoides pteronyssinus allergen 1 and 2 (Der 
p 1 and Der p 2), Endotoxin units (EU) 
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 FIGURE LEGENDS 
 
Figure 1. Mechanical heat recovery ventilation system. 
  
The mechanical heat recovery unit extracts air from the kitchen and bathroom (orange ducts) 
and delivers outdoor air warmed by exchanging heat in baffles with outgoing air via ducts 
into the bedroom and living room (red ducts). As designed and installed by ‘Vent-Axia’™ 
  
Figure 2 Study Profile 
 
Figure 3 Morning and evening peak expiratory flow measurements at baseline and 
during follow-up.  
 
(a) At 6 and 12 months, the change in mean morning peak expiratory flow (PEF), as 
compared with baseline, did not differ between the MHRV group and the control group 
(b) At 6 and 12 months, the change in mean evening PEF, as compared with baseline, was 
significantly greater in the MHRV (mechanical heat recovery ventilation) group compared to 
the control group [6 months, P=0.015 and at 12 months, P=0.002]. 
   
Figure 4 Relative humidity values and temperature over 12 months  
 
The fortnightly mean (standard deviation on one-side) relative humidity and temperature in 
the bedroom and living room show an annual periodicity with the lowest levels in March.  
MHRV reduced humidity in the bedrooms during April (* p<0.05) and then for a sustained 
period from October until February († p<0.001). The humidity in the living room was 
significantly reduced (* p<0.05) from December to February. There was no effect of MHRV 
on temperature. 
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Figure 1. Mechanical heat recovery ventilation system. 
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820 positive responses 
 
482 clinically screened 
 
216 clinically suitable 
120 MHRV units installed 
 
338 excluded by pre-
clinical screening or non-
attendance 
188 did not have positive 
skin test 
55 excluded 
43 withdrew 
4986 letters sent from 63 
practices and 2 clinics 
 
119 randomised 
47 placebo in per-protocol 
analysis 
54 MHRV-active in per-
protocol analysis 
 
1 non-attendance 
 
60 MHRV-active in 
intention-to-treat analysis 
 
    55 had 3 month data 
    55 had 6 month data 
    45 had 9 month data 
    53 had 12 month data  
 
59 placebo in intention-to-
treat analysis 
 
    46 had 3 month data 
    48 had 6 month data 
    38 had 9 month data 
    47 had 12 month data  
 
 
12 had protocol violations 
 
6  had protocol violations 
 
houses unsuitable 
declined unit  
 
er-pr tocol analysis 
had protocol violations 
Figure 2 Study profile 
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Figure 3 Morning and evening peak expiratory flow at baseline and during follow-up. 
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Figure 4 Relative humidity and temperature values over 12 months in MHRV and 
control groups 
 
 
